Health Status Prior and Post Infection With Influenza or COVID 19: a Population Based Retrospective Analysis of 2016-2021

• Sponsor: Medical University of Vienna (Other)
• Overall Status: Completed
• CT.gov ID: NCT05087355
• Collaborator: Landesklinikum Sankt Polten (Other), Sicknessfund Burgenland (BGKK) (Other), A.ö. Krankenhaus St. Josef Braunau GmbH (Other)
• Enrollment: 440,000
• Actual Duration (Months): 68

Study Details

Study Description

Brief Summary

The overall project aim is to study outcomes after COVID-19 and influenza hospitalisation from 2016 - 2021 by retrieving data from the main social security carriers in Austria for the years 2010-2018

Condition or Disease	Intervention/Treatment	Phase
Covid 19; Influenza	Diagnostic Test: PCR or antigen test for Covid 19 or Inluenza

Study Design

• Study Type: Observational
• Actual Enrollment: 440000 participants
• Observational Model: Cohort
• Time Perspective: Retrospective
• Official Title: Health Status Prior and Post Infection With Influenza or COVID 19: a Population Based Retrospective Analysis of 2016-2021
• Actual Study Start Date: Jan 1, 2016
• Actual Primary Completion Date: Aug 31, 2021
• Actual Study Completion Date: Aug 31, 2021

Arms and Interventions

Arm	Intervention/Treatment
Influenza	Diagnostic Test: PCR or antigen test for Covid 19 or Inluenza; PCR or antigen test for Covid 19 or Inluenza
Covid 19	Diagnostic Test: PCR or antigen test for Covid 19 or Inluenza; PCR or antigen test for Covid 19 or Inluenza
Control group hospitalisation due to other disease (not influenza or Covid 19)	Diagnostic Test: PCR or antigen test for Covid 19 or Inluenza; PCR or antigen test for Covid 19 or Inluenza

Outcome Measures

Primary Outcome Measures

1. Overall Mortality [5 years]

   Overall mortality after influenza or covid-19

2. age distribution [5 years]

   age distribution in patients with influenza or covid-19

3. risk profile [5 years]

   risk profile (e.g. prior diseases, medication) in patients who died due to influenza or covid-19

4. newly diagnosed diseases [5 years]

   newly diagnosed diseases after influenza or covid-19

5. newly prescribed medication [5 years]

   newly prescribed medication after influenza or covid-19

6. duration of hospitalisation or unemployability [5 years]

   duration of hospitalisation or unemployability after influenza or covid-19

Eligibility Criteria

Criteria

• Ages Eligible for Study: N/A and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Patients with SARS

• Patients with Covid-19

• Patients after Covid-19

• Patients with influenza

Exclusion Criteria:

• none

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• Medical University of Vienna
• Landesklinikum Sankt Polten
• Sicknessfund Burgenland (BGKK)
• A.ö. Krankenhaus St. Josef Braunau GmbH

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Hendrik Jan Ankersmit, Principal Investigator/Univ. Prof. , MD, MBA, Medical University of Vienna
• ClinicalTrials.gov Identifier: NCT05087355
• Other Study ID Numbers: AUTCOV-INFLU-STUDY
• First Posted: Oct 21, 2021
• Last Update Posted: Oct 29, 2021
• Last Verified: Oct 1, 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: COVID-19; Influenza, Human

Study Results

No Results Posted as of Oct 29, 2021